29586-66-1 Usage
Uses
Used in Biochemical Research:
H-LYS-ARG-OH is used as a building block for synthesizing longer peptides or proteins due to its free carboxylic acid group at the C-terminus, which facilitates peptide coupling reactions.
Used in Pharmaceutical Research:
H-LYS-ARG-OH is used as a potential therapeutic agent for various conditions, given its involvement in protein synthesis, cell signaling, and immune function. Its role in collagen formation, muscle growth, calcium absorption, and nitric oxide production may contribute to the development of treatments for related health issues.
Used in Drug Delivery Systems:
H-LYS-ARG-OH can be utilized as a carrier or component in drug delivery systems, leveraging its properties to enhance the delivery, bioavailability, and therapeutic outcomes of associated pharmaceuticals.
Used in Nutritional Supplements:
H-LYS-ARG-OH may be incorporated into nutritional supplements to support protein synthesis, muscle growth, and immune function, particularly for individuals with specific dietary needs or those seeking to optimize their intake of essential amino acids.
Check Digit Verification of cas no
The CAS Registry Mumber 29586-66-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,5,8 and 6 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 29586-66:
(7*2)+(6*9)+(5*5)+(4*8)+(3*6)+(2*6)+(1*6)=161
161 % 10 = 1
So 29586-66-1 is a valid CAS Registry Number.
29586-66-1Relevant academic research and scientific papers
Cell adhesion and extracellular matrix proteins
-
, (2008/06/13)
Various embodiments of the invention provide human cell adhesion and extracellular matrix proteins (CADECM) and polynucleotides which identify and encode CADECM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of CADECM.
Chimeric antibodies directed against a human glycoprotein antigen
-
, (2008/06/13)
The present invention discloses novel chimeric monoclonal antibodies, directed against proteoglycans of human melanoma cells, having antigen-specific variable regions of defined amino acid sequences. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are provided. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also provided.
